Neuregenix wins Biomedical Catalyst award

University of Birmingham Spinout Company is developing a novel drug for the treatment of Glaucoma

Scientists at the University of Birmingham have received funding from the Technology Strategy Board, the UK’s innovation agency, to develop a novel multi action siRNA drug with proven neuroprotective and neuroregenerative activity to treat Glaucoma.

Please download the full release as a PDF.

Published: March 21, 2013

website by whitespace